Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1

Trial Profile

A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mirikizumab (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms OASIS-1
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 06 Jul 2022 Results published in the British Journal of Dermatology
  • 25 Apr 2021 Primary endpoint (Percentage of Participants Achieving a 90% Improvement from Baseline in Psoriasis Area and Severity Score (PASI 90)) has been met, as per results presented at the American Academy of Dermatology Virtual Meeting Experience 2021.
  • 25 Apr 2021 Primary endpoint (Percentage of Participants with a Static Physicians Global Assessment of (sPGA) (0,1) with at Least a 2-point Improvement from Baseline) has been met, as per results presented at the American Academy of Dermatology Virtual Meeting Experience 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top